Brief: Pyc Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential As First Disease Modifying Therapy For Autosomal Dominant Optic Atrophy
29/06/2021 12:19
June 29 (Reuters) - PYC Therapeutics Ltd PYC.AX :
* PYC THERAPEUTICS ANNOUNCES COMPREHENSIVE PRECLINICAL
RESULTS
DEMONSTRATING VP-002 PROGRAM'S POTENTIAL AS FIRST DISEASE
MODIFYING THERAPY FOR AUTOSOMAL DOMINANT OPTIC ATROPHY
* PYC THERAPEUTICS LTD - EXPECT TO FILE IND APPLICATION WITH
FDA
IN FIRST HALF OF 2023
Source text for Eikon: ID:nPnpZ5w5a
Further company coverage: PYC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PYC Therapeutics
See all newsAustralia's PYC Therapeutics rises on EU orphan drug status
Brief: PYC Therapeutics Posts HY Revenues From Ordinary Activities A$11.0 Million
Brief: PYC Therapeutics Announces Raising Up To A$653 Million
Brief: PYC Therapeutics Seeks Trading Halt
Brief: PYC Therapeutics Says Rohan Hockings Re-Appointed As Managing Director